

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season**

as of April 2, 2019

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	4 <sup>a</sup> (2.7%)	9 <sup>b</sup> (0.7%)	9 <sup>b</sup> (0.7%)	0	0	125 (100%)	25 <sup>c</sup> (14.9%)	0	0	0	0	125 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	147	1,273	1,273	212	212	125	168	105	105	105	105	125	12	8	8	8	8
<b>Number of viruses reported</b>	2,437						3,099						90				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 0

<sup>b</sup> Patients without treatment 1

<sup>c</sup> Patients without treatment 3